TABLE 2.
Selected findings from abstracted clinical trials*
| Study | Comparators | Mean FEV1 (baseline % predicted) | Change from baseline | Relative risk (95% CI) |
|---|---|---|---|---|
| Calverley et al (17) | Salmeterol, n=372 | 44.3 | 73 mL | 0.93 |
| Salmeterol + fluticasone, n=358 | 44.8 | 133 mL | (0.801–1.08) | |
| Calverley et al (18) | Salmeterol, n=1521 | 43.6 | –21 mL | 0.88 |
| Salmeterol + fluticasone, n=1533 | 44.3 | 29 mL | (0.81–0.95) | |
| Calverley et al (19) | Formoterol, n=255 | 36.0 | 5% | 0.745 |
| Formoterol + budesonide, n=254 | 36.0 | 14% | (0.587–0.945) | |
| Szafranski et al (20) | Formoterol, n=201 | 36.0 | 14% | 0.771 |
| Formoterol + budesonide, n=208 | 36.0 | 15% | (0.599–0.992) |
*
Trials were identified via systematic review. FEV1 Forced expiratory volume in 1 s